Abivax: Positive FDA feedback ahead of obefazimod marketing authorization application filing
Abivax announced positive feedback from the FDA following its pre-NDA discussions concerning obefazimod. This regulatory validation occurs before the formal submission of the marketing authorization application.
Regulatory progress for obefazimod
French biotech company Abivax received a favorable opinion from the American FDA (Food and Drug Administration) following preliminary discussions prior to filing a New Drug Application (NDA). These pre-NDA exchanges, conducted before the formal submission of the approval request, allowed the company to validate its regulatory strategy for obefazimod.
This type of positive FDA feedback constitutes a standard milestone in the drug development process, where the agency outlines its expectations regarding the presentation of efficacy and safety data that will accompany the official application.
Commercial preparation context
This opinion comes a few days after the strengthening of Abivax's commercial management team, with the company having made four strategic appointments in marketing, patient services, sales and market access. These recruitments demonstrate Abivax's preparation for the commercial launch of obefazimod once regulatory approval is obtained.
